BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) and associated disturbances in Alzheimer's disease (AD) are a source of distress and burden for spouses, professional caregivers, and others with responsibilities for the care of individuals with AD. BPSD with behavioral disturbances are also associated with more rapid institutionalization and increased morbidity and mortality for persons with AD. OBJECTIVES: In this review and commentary, we discuss the history of the development of BPSD and behavioral disturbance assessments, which are distinct from those evaluating cognitive and functional symptoms of AD. In particular, we review the informant-based Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), the related, potentially more sensitive, BEHAVE-AD Frequency-Weighted Severity Scale (BEHAVE-AD-FW), and the direct subject evaluation-based Empirical BEHAVE-AD Rating Scale (E-BEHAVE-AD). The kinds of medications that alleviate behavioral symptoms on these measures as well as the problems and possibilities for further advances with these medications are discussed. Finally, the importance of distinguishing BPSD and behavioral disturbance remediation in AD from the treatment of cognitive decline and other aspects of AD is emphasized in the context of appropriate assessment methodology. The objective of this paper is to provide a framework for further advances in the treatment of BPSD and associated behavioral disturbances in AD and, consequently, a framework for continuing improvements in the lives of individuals with AD and those who share the burden of the disease with the AD person.
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) and associated disturbances in Alzheimer's disease (AD) are a source of distress and burden for spouses, professional caregivers, and others with responsibilities for the care of individuals with AD. BPSD with behavioral disturbances are also associated with more rapid institutionalization and increased morbidity and mortality for persons with AD. OBJECTIVES: In this review and commentary, we discuss the history of the development of BPSD and behavioral disturbance assessments, which are distinct from those evaluating cognitive and functional symptoms of AD. In particular, we review the informant-based Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), the related, potentially more sensitive, BEHAVE-AD Frequency-Weighted Severity Scale (BEHAVE-AD-FW), and the direct subject evaluation-based Empirical BEHAVE-AD Rating Scale (E-BEHAVE-AD). The kinds of medications that alleviate behavioral symptoms on these measures as well as the problems and possibilities for further advances with these medications are discussed. Finally, the importance of distinguishing BPSD and behavioral disturbance remediation in AD from the treatment of cognitive decline and other aspects of AD is emphasized in the context of appropriate assessment methodology. The objective of this paper is to provide a framework for further advances in the treatment of BPSD and associated behavioral disturbances in AD and, consequently, a framework for continuing improvements in the lives of individuals with AD and those who share the burden of the disease with the ADperson.
Authors: Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad Journal: Lancet Date: 2006-04-15 Impact factor: 79.321
Authors: M Bobinski; J Wegiel; M Tarnawski; M Bobinski; B Reisberg; M J de Leon; D C Miller; H M Wisniewski Journal: J Neuropathol Exp Neurol Date: 1997-04 Impact factor: 3.685
Authors: Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Barry Reisberg; Leslie Prichep; Lisa Mosconi; E Roy John; Lidia Glodzik-Sobanska; Istvan Boksay; Isabel Monteiro; Carol Torossian; Alok Vedvyas; Nauman Ashraf; Imran A Jamil; Mony J de Leon Journal: Alzheimers Dement Date: 2008-01 Impact factor: 21.566
Authors: Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman Journal: J Clin Psychiatry Date: 2003-02 Impact factor: 4.384
Authors: H S Levin; W M High; K E Goethe; R A Sisson; J E Overall; H M Rhoades; H M Eisenberg; Z Kalisky; H E Gary Journal: J Neurol Neurosurg Psychiatry Date: 1987-02 Impact factor: 10.154
Authors: Katherine P Rankin; Gianina Toller; Lauren Gavron; Renaud La Joie; Teresa Wu; Tal Shany-Ur; Patrick Callahan; Maggie Krassner; Joel H Kramer; Bruce L Miller Journal: Front Neurol Date: 2021-09-07 Impact factor: 4.086
Authors: Federico Rodriguez-Porcel; Kathryn A Wyman-Chick; Carla Abdelnour Ruiz; Jon B Toledo; Daniel Ferreira; Prabitha Urwyler; Rimona S Weil; Joseph Kane; Andrea Pilotto; Arvid Rongve; Bradley Boeve; John-Paul Taylor; Ian McKeith; Dag Aarsland; Simon J G Lewis Journal: Transl Neurodegener Date: 2022-05-02 Impact factor: 9.883
Authors: Luis Agüera-Ortiz; Ganesh M Babulal; Marie-Andrée Bruneau; Byron Creese; Fabrizia D'Antonio; Corinne E Fischer; Jennifer R Gatchel; Zahinoor Ismail; Sanjeev Kumar; William J McGeown; Moyra E Mortby; Nicolas A Nuñez; Fabricio F de Oliveira; Arturo X Pereiro; Ramit Ravona-Springer; Hillary J Rouse; Huali Wang; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160